Publications by authors named "Rui-Qing Cai"
Purpose: Although burnout recently emerged as a harmful syndrome in parents, no instrument has been validated to suitably assess burnout among parents of children with cancer in China. In this study, we aimed to psychometrically validate the Shirom-Melamed Burnout Questionnaire (SMBQ) among Chinese parents of children with cancer.
Design And Methods: We conducted a cross-sectional survey of 380 parents of children with cancer to psychometrically validate the SMBQ.
Quality of life and related demographic factors in long-term survivors of childhood non-Hodgkin's lymphoma.
Zhongguo Dang Dai Er Ke Za Zhi
September 2021
Objectives: To evaluate the quality of life and related demographic factors in long-term survivors of childhood non-Hodgkin's lymphoma (NHL).
Methods: A retrospective analysis was performed on the medical and demographic data of the NHL patients who received treatment in the Sun Yat-sen University Cancer Center and achieved long-term survival at follow-up, with an age of <18 years at initial diagnosis and a present age of ≥18 years. A questionnaire survey was performed using 36-Item Short-Form Health Survey (SF-36) and the symptom subscale of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30).
Introduction: Brain metastasis is common in relapsed neuroblastoma patients, but the characteristics of brain metastasis remain largely unknown. This study aimed to investigate the status of brain metastasis with neuroblastoma in South China.
Methods: In this retrospective case-based study, 106 patients with stage 4 neuroblastoma from the Department of Pediatric Oncology in Sun Yat-sen University Cancer Center between January 2004 and May 2013 were included.
Article Synopsis
- This study focused on primary central nervous system germ cell tumors (CNS-GCTs) in Chinese children and adolescents, highlighting their clinical characteristics and treatment results over a 10-year period from 2002 to 2012.
- Of the 57 patients analyzed, the majority were male, with a median age of 12.8 years; most had non-germinomatous germ cell tumors (NGGCTs) and localized disease.
- Results showed that patients who received multimodality therapies, like the PEB chemotherapy alongside surgery or radiotherapy, had significantly better survival rates compared to those who underwent monotherapy.
Objective: To evaluate the efficacy of a modified NHL-BFM-90 protocol in childhood and adolescence with Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL).
Methods: A total of 138 de novo patients with BL and DLBCL were enrolled. All patients were stratified into low (R1), intermediate (R2) and high risk (R3) groups based on the stage, chemotherapy response and LDH level, and treated with a modified NHL-BFM 90 protocol.
Lymphoma is seen in up to 30% of patients with X-linked lymphoproliferative disease (XLP), but cerebral vasculitis related with XLP after cure of Burkitt lymphoma is rarely reported. We describe a case of a 5-year-old boy with XLP who developed cerebral vasculitis two years after cure of Burkitt lymphoma. He had Burkitt lymphoma at the age of 3 years and received chemotherapy (non-Hodgkin's lymphoma-Berlin-Frankfurt-Milan-90 protocol plus rituximab), which induced complete remission over the following two years.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the safety of in vitro amplified HLA-haploidentical donor immune cell infusion (HDICI) in 12 children with various malignancies, primarily neuroblastoma, at Sun Yat-sen University Cancer Center between 2011 and 2012.
- Out of the patients, a significant majority showed positive responses to treatment; 7 of 9 with neuroblastoma achieved complete response, while some experienced mild side effects like fever and emotional changes, with no severe adverse events reported.
- The findings suggest that HDICI is a safe immunotherapy option for treating childhood cancers and indicate the need for further research into its efficacy.
Article Synopsis
- * Most patients (63.2%) presented with advanced stage disease (III/IV), and the study found that around 57.8% of patients belonged to the germinal-center B-cell (GCB) subtype, while 42.2% were non-GCB.
- * The modified B-NHL-BFM-90/95 treatment regimen showed an impressive 4-year event-free survival rate of 85.8%, demonstrating its effectiveness for this pediatric population.
Angioimmunoblastic T-cell lymphoma (AITL) is a rare, distinct subtype of peripheral T-cell lymphoma, possessing an aggressive course and poor prognosis with no standard therapy. Twelve patients who have failed at least two initial CHOP or CHOP-like regimens were enrolled in this study and treated with individualized cyclosporine (CsA), prednisone (PDN), and monthly, high-dose intravenous immunoglobulin (HDIVIG). The dose of CsA was adjusted individually based on the blood trough concentration of CsA and renal function.
View Article and Find Full Text PDF